ImmunoCellular Therapeutics, Ltd. (IMUC) Completes Interim Analysis of ICT-107 Phase 2 Clinical Trials
ImmunoCellular Therapeutics, a clinical-stage company developing immune-based therapies for the treatment of brain and other cancers, today said that the Data Monitoring Committee (DMC) has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in patients with newly diagnosed glioblastoma. Furthermore, DMC recommended that the company continue the trial to completion, which the company anticipates will be by year end. The ICT-107 study is structured so that interim analysis is conducted by the independent DMC after 32 events (patient deaths) are reached – IMUC remains blinded to the actual results and details of the interim analysis as…